Latest Thrombocytopenia Stories
Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage.
By Naina, Harris V K Harris, Samar; Pham, Angie; Wang, Jun To the Editor.-In the review article on Bernard-Soulier syndrome (BSS), Pham and Wang1 reported the May-Hegglin anomaly as the most common inherited giant platelet disorder. We disagree with the authors regarding that statement.
WOODCLIFF LAKE, N.J., Sept. 15 /PRNewswire/ -- Eisai Inc. announced today its support of the Acting Surgeon General's Call to Action on venous thromboembolism (VTE), a serious and potentially life-threatening condition that includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
Cleveland BioLabs, a drug discovery and development company, has received a $774,183 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic damage from radiation exposure.
Cleveland BioLabs, Inc.
Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura.
The U.S. Food and Drug Administration says it has approved Nplate (romiplostim), the first product that directly stimulates bone marrow platelet production. The FDA said the new drug will be used to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.
By Fareed, J Iqbal, O; Cunanan, J; Demir, M; Wahi, R; Clarke, M; Adiguzel, C; Bick, R The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin.
Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS).